T cells engineered to target a shared β-catenin mutation eradicate solid tumors in mice



Summary

Genetically engineered T cells targeting a specific mutation in the β-catenin protein have shown remarkable success in eradicating solid tumors in mice. This mutation, often found in various cancers, is a promising target due to its presence inside the tumor cells, posing a delivery challenge. Researchers developed T cells engineered with a specific T cell receptor that can recognize and bind to the mutated β-catenin protein when presented on MHC molecules. The study demonstrated that these engineered T cells effectively eliminated tumor cells expressing the mutated protein, leading to complete tumor regression in preclinical mouse models, highlighting the potential of this targeted immunotherapy approach for treating solid tumors.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!